Smartphone-based Mobile Applications for Adverse Drug Reactions Reporting: Global Status and Country Experience

Overview

Journal BMC Med Inform Decis Mak

Publisher Biomed Central

Specialty Medical Informatics

Date 2022 May 3

PMID 35501745

Authors

Ayako Fukushima

Noha Iessa

Madhava Ram Balakrishnan

Shanthi Narayan Pal

Affiliations

Soon will be listed here.

Abstract

Background: Smartphone technology can support paperless reporting of adverse drug reactions (ADRs). The aims of this study were to systematically assess smartphone ADR-reporting applications, understand their qualitative and quantitative impact on ADR reporting, and garner key lessons from owners and developers.

Methods: This study had three components: (1) An assessment of ADR-reporting apps, (2) an online survey on the impact of app implementation on ADR reporting and the experiences of app developers and owners, and (3) a search of VigiBase, the World Health Organization global database of individual case safety reports (ICSRs), to observe trends in the number of ADR reports targeting countries where the apps were implemented.

Results: Twenty-two apps were included. Eight out of the 22 apps were for countries in the WHO African region. Features observed included E2B data elements (E stands for efficacy) and functions supporting reporting and user engagement. Seventeen app developers and owners answered to the survey and reported overall positive experiences with app features, and post-launch increases in the total number of ICSRs. User type and user environment were cited as factors influencing app use: Respondents said younger people and/or those with an inclination to use technology were more likely to use apps compared to older or more technology-averse people, while respondents in countries with limited internet connectivity reported persistent difficulties in app use.

Conclusions: Smartphone apps for reporting ADRs offer added value compared to conventional reporting tools. Reporting tools should be selected based on interface features and factors that may influence app usage.

Citing Articles

Impact of in-service training on the knowledge, attitude, and practice of pharmacovigilance in Malawi: a cross-sectional mixed methods study.

Chiumia F, Dzabala N, Ndalama A, Sambakunsi C, Raguenaud M, Merle C Malawi Med J. 2025; 36(3):163-169.

PMID: 40018398 PMC: 11862858. DOI: 10.4314/mmj.v36i3.2.

e-Health applications for outpatient professional pharmaceutical care services: A scoping review.

Agudelo R, Pereanez J, Munoz S, Granados J, Ceballos M Explor Res Clin Soc Pharm. 2025; 17:100567.

PMID: 39926416 PMC: 11803173. DOI: 10.1016/j.rcsop.2025.100567.

Effectiveness of the modified TaWai mobile application for reporting adverse drug reaction in Lao PDR: a cluster randomized controlled trial.

Mongkhonmath N, Olson P, Puttarak P, Keokinnaly S, Sawangjit R Sci Rep. 2024; 14(1):31161.

PMID: 39730897 PMC: 11681246. DOI: 10.1038/s41598-024-82474-9.

Consumer views on the use of digital tools for reporting adverse drug reactions: a cross-sectional study.

Dedefo M, Lim R, Kassie G, Gebreyohannes E, Salekdeh N, Roughead E Int J Clin Pharm. 2024; .

PMID: 39699849 DOI: 10.1007/s11096-024-01847-2.

Views on the Development and Use of a New Digital Adverse Drug Event Reporting Platform in Australia: A Qualitative Study.

Gebreyohannes E, Thornton C, Thiessen M, de Vries S, Coombs G, Hwang I Drug Saf. 2024; 48(2):179-190.

PMID: 39487335 PMC: 11785647. DOI: 10.1007/s40264-024-01489-3.

References

Potlog Shchory M, Goldstein L, Arcavi L, Shihmanter R, Berkovitch M, Levy A . Increasing adverse drug reaction reporting-How can we do better?. PLoS One. 2020; 15(8):e0235591. PMC: 7425892. DOI: 10.1371/journal.pone.0235591. View

Prakash J, Joshi K, Malik D, Mishra O, Sachan A, Kumar B . "ADR PvPI" Android mobile app: Report adverse drug reaction at any time anywhere in India. Indian J Pharmacol. 2019; 51(4):236-242. PMC: 6759532. DOI: 10.4103/ijp.IJP_595_18. View

Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D . Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2012; 69(2):237-44. DOI: 10.1007/s00228-012-1321-7. View

Kim B, Sharafoddini A, Tran N, Wen E, Lee J . Consumer Mobile Apps for Potential Drug-Drug Interaction Check: Systematic Review and Content Analysis Using the Mobile App Rating Scale (MARS). JMIR Mhealth Uhealth. 2018; 6(3):e74. PMC: 5895923. DOI: 10.2196/mhealth.8613. View

Ampadu H, Hoekman J, de Bruin M, Pal S, Olsson S, Sartori D . Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. Drug Saf. 2016; 39(4):335-45. PMC: 4796322. DOI: 10.1007/s40264-015-0387-4. View

Pierce C, de Vries S, Bodin-Parssinen S, Harmark L, Tregunno P, Lewis D . Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR. Drug Saf. 2019; 42(4):477-489. PMC: 6450855. DOI: 10.1007/s40264-019-00813-6. View

van Stekelenborg J, Ellenius J, Maskell S, Bergvall T, Caster O, Dasgupta N . Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Saf. 2019; 42(12):1393-1407. PMC: 6858385. DOI: 10.1007/s40264-019-00858-7. View

Iessa N, Sarinic V, Ghazaryan L, Romanova N, Alemu A, Rungapiromnan W . Smart Safety Surveillance (3S): Multi-Country Experience of Implementing the 3S Concepts and Principles. Drug Saf. 2021; 44(10):1085-1098. PMC: 8325038. DOI: 10.1007/s40264-021-01100-z. View

Tandon V, Mahajan V, Khajuria V, Gillani Z . Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian J Pharmacol. 2015; 47(1):65-71. PMC: 4375822. DOI: 10.4103/0253-7613.150344. View

10.

Herdeiro M, Ribeiro-Vaz I, Ferreira M, Polonia J, Falcao A, Figueiras A . Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf. 2012; 35(8):655-65. DOI: 10.1007/BF03261962. View

11.

Oosterhuis I, Taavola H, Tregunno P, Mas P, Gama S, Newbould V . Characteristics, Quality and Contribution to Signal Detection of Spontaneous Reports of Adverse Drug Reactions Via the WEB-RADR Mobile Application: A Descriptive Cross-Sectional Study. Drug Saf. 2018; 41(10):969-978. PMC: 6153975. DOI: 10.1007/s40264-018-0679-6. View

12.

Olsson S, Pal S, Dodoo A . Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015; 8(4):449-60. DOI: 10.1586/17512433.2015.1053391. View

13.

Ghosh R, Kempf D, Pufko A, Barrios Martinez L, Davis C, Sethi S . Automation Opportunities in Pharmacovigilance: An Industry Survey. Pharmaceut Med. 2020; 34(1):7-18. DOI: 10.1007/s40290-019-00320-0. View

14.

Kiguba R, Ndagije H, Nambasa V, Bird S . Adverse Drug Reaction Onsets in Uganda's VigiBase: Delayed International Visibility, Data Quality and Illustrative Signal Detection Analyses. Pharmaceut Med. 2018; 32(6):413-427. PMC: 6267548. DOI: 10.1007/s40290-018-0253-7. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

16.

Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V . Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP: A Comparison with Classical Methods of Reporting. Drug Saf. 2017; 41(5):511-514. DOI: 10.1007/s40264-017-0630-2. View

17.

de Vries S, Denig P, Lasheras Ruiz C, Houyez F, Wong L, Sutcliffe A . Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients. Drug Saf. 2018; 41(7):697-712. PMC: 5990568. DOI: 10.1007/s40264-018-0648-0. View

18.

Mosa A, Yoo I, Sheets L . A systematic review of healthcare applications for smartphones. BMC Med Inform Decis Mak. 2012; 12:67. PMC: 3534499. DOI: 10.1186/1472-6947-12-67. View

19.

Defer G, Le Caignec F, Fedrizzi S, Montastruc F, Chevanne D, Parienti J . Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. Trials. 2018; 19(1):174. PMC: 5845183. DOI: 10.1186/s13063-018-2560-4. View

20.

Chen Y, Niu R, Xiang Y, Wang N, Bai J, Feng B . The Quality of Spontaneous Adverse Drug Reaction Reports in China: A Descriptive Study. Biol Pharm Bull. 2019; 42(12):2083-2088. DOI: 10.1248/bpb.b19-00637. View